Darifenacin Tablet, Extended Release
Product Images NDC 33342-276

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Darifenacin (NDC 33342-276). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Macleods Pharmaceuticals Limited, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Structure (Darifenacin Structure)

Chemical structure of Darifenacin, showing the molecular arrangement of its atoms and bonds corresponding to the active ingredient Darifenacin in the product.*

FDA Label Image

Darifenacin Tab 15mg 30s Container

Darifenacin Extended-Release Tablets 15 mg package label from Macleods Pharmaceuticals Limited. The label includes dosage strength 15 mg, quantity of 30 tablets, and mentions extended-release tablet form. It specifies storage conditions and manufacturer information for Macleods Pharma USA, Inc. and Macleods Pharmaceuticals Ltd.*

FDA Label Image

Darifenacin Tab 15mg 90s Container

Darifenacin Extended-Release Tablets 15 mg by Macleods Pharma USA. This label shows a 90-tablet bottle with the active ingredient darifenacin hydrobromide providing 15 mg darifenacin per tablet. It includes storage instructions, usual dosage, barcodes, and manufacturer details of Macleods Pharmaceuticals Ltd. in India and Macleods Pharma USA, Inc.*

FDA Label Image

Darifenacin Tab 7 5mg 30s Container

Darifenacin Extended-Release Tablets 7.5 mg label from Macleods Pharma USA, Inc. The label states that each extended-release tablet contains 8.923 mg of darifenacin hydrobromide to provide 7.5 mg darifenacin. It includes storage instructions, usual dosage as one tablet daily, and package quantity of 30 tablets. Manufactured by Macleods Pharmaceuticals Ltd., Baddi, Himachal Pradesh, India.*

FDA Label Image

Darifenacin Tab 7 5mg 90s Container

Darifenacin Extended-Release Tablets 7.5 mg label from Macleods Pharmaceuticals Limited. The label includes drug strength prominently highlighted and mentions a package size of 90 tablets. Storage instructions and manufacturer information for Macleods Pharma USA, Inc. and Macleods Pharmaceuticals Ltd. in India are also visible. The design includes barcodes and text advising pharmacists to dispense the patient information leaflet.*

FDA Label Image

Figure-1 (Darifenacin Tab Figure 1)

A line graph showing mean (SD) Darifenacin plasma concentration (ng/mL) over time post-dose (hours) for 7.5 mg and 15 mg oral doses. The 15 mg dose shows higher plasma concentration levels compared to the 7.5 mg dose throughout the 24-hour period measured. Error bars indicate variability (SD) at each time point.*

FDA Label Image

Figure-2a (Darifenacin Tab Figure 2a)

A line chart illustrating the median reduction in incontinence episodes per week over 12 weeks, comparing Placebo, Darifenacin 7.5 mg, and Darifenacin 15 mg. The y-axis shows reduction from baseline with 95 percent confidence intervals, and the x-axis represents time in weeks. Darifenacin 15 mg shows the greatest reduction, followed by 7.5 mg, then Placebo.*

FDA Label Image

Figure-2b (Darifenacin Tab Figure 2b)

A line graph showing median reduction of incontinence episodes per week from baseline over 12 weeks for Darifenacin extended-release tablets at 7.5 mg and 15 mg doses compared to placebo. The vertical axis shows median reduction with 95% confidence intervals, and the horizontal axis shows time in weeks up to 12. Darifenacin 15 mg shows the greatest reduction, followed by 7.5 mg and then placebo.*

FDA Label Image

Figure-2c (Darifenacin Tab Figure 2c)

A line graph comparing the median reduction in incontinence episodes per week from baseline over 12 weeks between placebo and Darifenacin 15 mg. The y-axis shows median reduction with 95 percent confidence intervals, and the x-axis shows time in weeks. Darifenacin 15 mg demonstrates a greater reduction than placebo at each time point.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.